Ambrx Biopharma Cayman, Inc. — key financial figures for fiscal year 2022 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2022)

$7.4M

Net Income/Loss (FY2022)

-$78.0M

Total Assets (FY2022)

$147.0M

Total Equity (FY2022)

$117.8M

Cash Flows from Operating Activities (FY2022)

-$68.7M

Source: Ambrx Biopharma Cayman, Inc. 10-K filing (FY2022). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.